Verrica
NASDAQ: VRCAWest Chester, US · Founded 2013 · 87 employees on LinkedIn · 2 known investors
Find your way into Verrica
Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma. Its products serve dermatology prescribers, payers, and patients, with a lead drug-device combination based on topical cantharidin.
Founders & leadership
NR
JK
John KirbyExecutive
MD
Matthew DavidsonNamed on SEC filing
Board
JR
PB
DZ
SS
MP
Mark PrygockiBoard director
DN
Diem NguyenBoard director
GC
Gavin CorcoranBoard director
LE
Lawrence EichenfieldBoard director
GO
Glenn OclassenBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$77.5M disclosed across 4 of 5 rounds · 1900–2025
▶$50MraisedDec 2025 · 21 investors · PharmaceuticalsRule 506(b)
▶$50MraisedDec 2025 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark PrygockiDirector
- Noah RosenbergExecutive Officer
- Diem NguyenDirector
- John KirbyExecutive Officer
- Gavin CorcoranDirector
- Jayson RiegerExecutive Officer, Director
- Paul B. ManningDirector
- David ZawitzExecutive Officer
- Lawrence EichenfieldDirector
- Sean StalfortDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $500.2K
- Placement agents
- TD Securities (USA) LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedFeb 2018 · 2 investors · PharmaceuticalsRule 506(b)
▶$20MraisedFeb 2018 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Glenn OclassenDirector, Promoter
- Joseph BonaccorsoExecutive Officer
- Sean StalfortDirector, Promoter
- Ted WhiteExecutive Officer
- Paul ManningDirector, Promoter
- Anthony CavalloExecutive Officer
- James C. ReebalsExecutive Officer, Promoter
- Matthew DavidsonExecutive Officer, Director, Promoter
- Jayson RiegerExecutive Officer, Director, Promoter
- Offering amount
- $21M
- Amount sold
- $20M
- Minimum investment
- $25K
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$5MraisedDec 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedDec 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sean StalfortDirector, Promoter
- Matthew DavidsonExecutive Officer, Director, Promoter
- Paul ManningExecutive Officer, Director, Promoter
- James C. ReebalsExecutive Officer, Promoter
- Jayson RiegerExecutive Officer, Director, Promoter
- Glenn OclassenDirector, Promoter
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $5M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$2.4MraisedDec 2015 · 14 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedDec 2015 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew DavidsonExecutive Officer, Director
- Jayson RiegerDirector
- Glenn OclassenDirector
- Sean StalfortDirector
- Paul ManningDirector
- Amount sold
- $2.4M
- Sales commissions
- $52.5K
- Placement agents
- IMS Health Capital, Inc.
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$299.2Mvaluation at IPOJun 2018 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Verrica Schedules Aug. 6 Earnings Call With Corporate Update - MyChesComychesco.com · Aug 2026Frequently asked questions
- What does Verrica do?
- Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma. Its products serve dermatology prescribers, payers, and patients, with a lead drug-device combination based on topical cantharidin.
- Who are Verrica's investors?
- Verrica's investors include OrbiMed, PBM Capital.
- How much funding has Verrica raised?
- Verrica has disclosed $77.5M raised across 4 of its 5 known rounds.
- Where is Verrica headquartered?
- Verrica is headquartered in West Chester, US.